Individual Bioequivalence Interim Approach Proposed To Gather More Data
Executive Summary
An expert panel assembled by FDA is proposing that the agency adopt an interim approach to new bioequivalence methods, panel member Leslie Benet, PhD, University of California(San Francisco, told an American Association of Pharmaceutical Scientists workshop held March 16-18 in Arlington, Va.
You may also be interested in...
Individual BE Replicate Study Design To Be Analyzed Over Two Years By FDA
FDA is planning to conduct a two-year evaluation of its recommended replicate design method to determine whether a transition away from average bioequivalence criterion and towards individual and population BE criteria should occur.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011